Bone alkaline phosphatase isoenzyme in renal osteodystrophy.

Nephrology Service, Hospital Universitario Virgen Macarena, Seville, Spain.
Nephrology Dialysis Transplantation (Impact Factor: 3.37). 01/1996; 11 Suppl 3:43-6.
Source: PubMed

ABSTRACT Serum total alkaline phosphatase is the most commonly used biochemical marker of bone disease in renal patients, but alkaline phosphatase originates from different organs and sometimes lacks specificity. Bone isoenzyme measurement is considered superior to total alkaline phosphatase for the assessment of bone metabolism. We have studied the value of bone isoenzyme, determined by a new. IRMA (Tandem-R-Ostase), in haemodialysis patients with secondary hyperparathyroidism and renal osteodystrophy. Fifty-six haemodialysis patients were studied. Intact parathyroid hormone (PTH), osteocalcin, total alkaline phosphatase and bone alkaline phosphatase were determined. A transiliac bone biopsy was performed in 20 of the 56 patients after double tetracycline labelling. There was a significant correlation between bone alkaline phosphatase and PTH (r = 0.79, P < 0.001) and between bone and total alkaline phosphatase (r = 0.84, P < 0.001) in all patients. The patients who underwent a bone biopsy showed osteitis fibrosa in 17, mixed lesion in one, adynamic bone disease in one and normal bone in one. Bone alkaline phosphatase showed a significant correlation with static and dynamic histomorphometric indices similar to that obtained with PTH and better than those of total alkaline phosphatase and osteocalcin. It is concluded that bone alkaline phosphatase (ostase) seems to be a useful non-invasive marker of bone metabolism in patients on haemodialysis with high turnover bone disease. More studies are necessary to know its value in low turnover bone disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Overall and cardiovascular mortality in patients with chronic kidney disease (CKD) is greatly increased, without obvious current effective treatments. Mineral and bone disorder (MBD) is a common manifestation of CKD and contributes to the high risk of fracture and cardiovascular mortality in these patients. Traditionally, clinical management of CKD-MBD focused on attenuation of secondary hyperparathyroidism due to impaired renal activation of vitamin D and phosphate retention, although recently, adynamic forms of renal bone disease have become more prevalent. Definitive diagnosis was based on histologic (histomorphometric) analysis of bone biopsy material supported by radiologic changes and changes in levels of surrogate laboratory markers. Of these various markers, parathyroid hormone (PTH) has been considered to be the most sensitive and currently is the most frequently used; however, the many pitfalls of measuring PTH in patients with CKD increasingly are appreciated. We propose an alternative or complementary approach using bone alkaline phosphatase (ALP), which is directly related to bone turnover, reflects bone histomorphometry, and predicts outcomes in hemodialysis patients. Here, we consider the overall merits of bone ALP as a marker of bone turnover in adults with CKD-MBD, examine published bone histomorphometric data comparing bone ALP to PTH, and discuss possible pathogenic mechanisms by which bone ALP may be linked to outcomes in patients with CKD.
    American Journal of Kidney Diseases 04/2013; · 5.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal osteodystrophy (ROD) has never been studied on the small Mediterranean island of Malta, which has a largely inbred population. The genetic contribution to the pattern of renal osteodystrophy is being increasingly recognized. We were, thus, interested in studying indices of bone turnover in Maltese end stage renal failure patients. Sixty unselected patients, representing 65% of all patients undergoing dialysis in the island's renal unit, were prospectively investigated over a period of 5 months with respect to symptoms, calcium/phosphate chemistry, intact parathyroid hormone (iPTH) and bone alkaline phosphatase (bAP). Bone histomorphometry, which is the gold standard in the diagnosis of ROD, was not within the reach of our small unit. Biochemical markers may not be as sensitive and specific as bone biopsy for individual patient diagnosis of ROD sub-type but they can give a fairly good indication of the spectrum of bone turnover on a population basis. The optimum combination of biochemical marker cut-offs available from studies in the literature was then employed to estimate bone turnover. The following biochemical picture emerged: 42% had iPTH < 79.7 pg/ml (which cut off has a reported specificity of 93.7% for low turnover bone disease), 45% had iPTH > 100 pg/ml and bAP > 10 ng/ml (which combined cut off has a reported specificity of 100% for high turnover bone disease), while 13% could not be classified (ie had intermediate values). Based on biochemical data, the pattern of bone turnover seems to be comparable to the European average. Further indepth study using bone histomorphometry is warranted.
    International Urology and Nephrology 02/2005; 37(2):335-40. · 1.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone alkaline phosphatase (bAP) is known to be an important biochemical marker of bone formation. Through the present study, we intended to find out whether there is any advantage in bAP determination, as a routine biochemical marker, besides intact parathyroid hormone (iPTH) in hemodialysis patients. In a population of 140 hemodialysis patients, bAP and iPTH were determined on four quarterly consecutive occasions. According to the values of iPTH (pg/ml) and bAP (ng/ml), patients were divided into four groups: group I: iPTH > 200 and bAP > 20, group II: iPTH > 200 and bAP < 20, group III: iPTH < 200 and bAP < 20 and group IV: iPTH < 200 and bAP > 20. Patients with higher serum phosphorus (P) (group A: P > or = 7 mg/dl) were compared with those with lower serum P levels (group B: P < 7 mg/dl). The global correlation between iPTH and bAP (total evaluations, n = 503) was 0.32 (p < 0.001). Group IV patients tended to show a slight increase of serum aluminum (sAl) levels, which were 12.48 +/- 5.35 microg/l higher than in the patients from group I (sAl = 9.97 +/- 4.39 microg/l), group II (sAl = 10.86 +/- 4.45 microg/l) or group III (sAl = 10.92 +/- 3.92 microg/l). Significance values (Mann-Whitney) in each group, in comparison with group IV, were the following: group I: 0.004; group II: 0.062; group III: < 0.001. Group A (n = 66) showed higher iPTH levels than group B (n = 430), although bAP and sAl were both similar in these two groups of patients (Mann-Whitney): iPTH (A) = 631.0 +/- 487.7 vs. iPTH (B) = 253.3 +/- 191.6, p < 0.001; bAP (A) = 22.9 +/- 17.4 vs. bAP (B) = 20.4 +/- 13.1, p = n.s.; sAl (A) = 10.2 +/- 3.5 vs. sAl (B) = 10.8 +/- 4.4, p = n.s. For similar Al and bAP values, group A showed a much stronger iPTH/bAP correlation than group B: r = 0.67 (p < 0.001) vs. r = 0.30 (p < 0.001), respectively. Although iPTH and bAP are frequently in agreement, it seems important to separate parathyroid activity given by iPTH, from bone remodelling reflected by bAP, in the presence of either a higher aluminum exposition or a well-controlled phosphatemia.
    Nephron Clinical Practice 02/2005; 101(3):c122-7. · 1.65 Impact Factor


Available from